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Dyslipidemia and atherosclerosis are associated
with reduced insulin sensitivity and diabetes, but
the mechanism is unclear. Gain of function of the
gene encoding deacetylase SirT1 improves insulin
sensitivity and could be expected to protect against
lipid abnormalities. Surprisingly, when transgenic
mice overexpressing SirT1 (SirBACO) are placed on
atherogenic diet, they maintain better glucose
homeostasis, but develop worse lipid profiles and
larger atherosclerotic lesions than controls. We
show that transcription factor cAMP response
element binding protein (Creb) is deacetylated in Sir-
BACO mice. We identify Lys136 is a substrate for
SirT1-dependent deacetylation that affects Creb
activity by preventing its cAMP-dependent phos-
phorylation, leading to reduced expression of gluco-
genic genes and promoting hepatic lipid accumula-
tion and secretion. Expression of constitutively
acetylated Creb (K136Q) in SirBACO mice mimics
Creb activation and abolishes the dyslipidemic and
insulin-sensitizing effects of SirT1 gain of function.
We propose that SirT1-dependent Creb deacetyla-
tion regulates the balance between glucose and lipid
metabolism, integrating fasting signals.
INTRODUCTION
Patients with type 2 diabetes develop more severe and more
extensive atherosclerosis that contributes to their increased
risk of cardiovascular disease (CVD) and related mortality
(National Institute of Diabetes and Digestive and Kidney
Diseases, 2005). Thus, it is important to understand the mecha-
nism linking diabetes and atherosclerosis. Insulin resistance is
a prominent feature of type 2 diabetes and an independent risk
factor for atherosclerosis (Howard et al., 1996). The mechanism
linking dyslipidemia with insulin action remains unclear (Haeusler
and Accili, 2008), but alterations of hepatic insulin sensitivity are758 Cell Metabolism 14, 758–767, December 7, 2011 ª2011 Elseviersufficient to bring about changes of lipid metabolism reminiscent
of diabetic dyslipidemia (Biddinger et al., 2008; Han et al., 2009).
We and others have reported that genetic gain of function and
pharmacologic activation of theNAD+-dependent protein deace-
tylase SirT1 improve insulin sensitivity in rodents (Banks et al.,
2008;Baur et al., 2006;Pfluger et al., 2008).Moreover, SirT1over-
expression in endothelial cells increases endothelial nitric oxide
synthase (eNOS) function (Chen et al., 2008; Li et al., 2007; Zhang
et al., 2008), and sirtuins reduce inflammation in the vessel wall
and improve hepatic and macrophage cholesterol metabolism
(Chen et al., 2008; Li et al., 2007). These and germane findings
(Schwer and Verdin, 2008) raise the question of whether the
insulin-sensitizing effects of sirtuins can prevent atherosclerosis.
Toanswer thisquestion,weplaced transgenicmicecarryingan
extra copy of the Sirt1 gene (Banks et al., 2008) on a cholesterol-
rich (Western-type) diet (WTD) anddetermined their susceptibility
to dyslipidemia and atherosclerosis. Surprisingly, we show that
SirT1 gain of function has detrimental effects on lipidmetabolism,
despite its beneficial effects on glucose metabolism. We show
that these effects are associated with deacetylation-dependent
inhibition of the cAMP response element binding protein (Creb).
Creb promotes hepatic gluconeogenesis (Chrivia et al., 1993)
and inhibits lipid synthesis (Herzig et al., 2003). Its activity is regu-
lated by several cofactors, two of which—Torc2 and Cbp—are
also deacetylated by SirT1 (Liu et al., 2008). However, it’s
unknown whether Creb itself is a SirT1 substrate and how this
might affect the cAMP response.We report that SirT1 directly de-
acetylates Creb and identify Lys136 as a site of SirT1-dependent
Creb deacetylation that modulates its protein kinase A (PKA)-
dependentphosphorylation.Wedemonstrate thataconstitutively
acetylated Creb mutant (K136Q) reverses the effects of SirT1 on
hepatic lipid synthesis anddeposition, aswell as glucose homeo-
stasis, indicating that Creb deacetylation plays a central role in
theparadoxical dissociationbetweenglucoseand lipidmetabolic
effects observed in SirT1 transgenics.
RESULTS
Increased Dyslipidemia and Atherosclerosis
in SirBACO:Ldlr–/ Mice
To test the effects of SirT1 gain of function on lipid metabolism
and atherosclerosis, we intercrossed SirT1-transgenic miceInc.
Figure 1. Metabolic Characterizations of WTD-Fed SirBACO:Ldlr–/–
Mice
(A and B) IPGTT time courses (A) and areas under the curve (B) (*p < 0.05, n = 5
each).
(C–E) Measurements of fasting plasma glucose (C), total cholesterol (D), and
TG (E) (**p < 0.01, *p < 0.05, n = 18–24).
(F and G) FPLC fractionation of lipoprotein cholesterol (F) and TG (G) in pooled
sera (six mice each). All measurements were carried out after a 5 hr fast.
(H) Measurements of aortic root lesion areas following 14 weeks on WTD (*p <
0.05, n = 15–19 each). A horizontal line indicates mean area in each group.
(I) H&E staining of representative aortic root lesions, with arrows indicating
cholesterol clefts and asterisks indicating necrotic cores. Data are expressed
as means ± SEM.
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(Banks et al., 2008) and Ldlr/ mice, subjected double mutant
mice to WTD, and analyzed the resulting phenotypes.
SirBACO:Ldlr/ mice displayed better glucose tolerance
(Figures 1A and 1B) and lower fasting glucose than Ldlr/
controls (Figure 1C). Strikingly, the improvement of glucose
metabolism was associated with a worsening lipid profile, char-
acterized by increased total cholesterol (Figure 1D), a trend
toward increased triglycerides (TG) (Figure 1E), and elevated
VLDL and LDL cholesterol and VLDL-TG (Figures 1F and 1G).
These changes were not present in mice fed standard chow
(Figures S1A–S1D) and were independent of changes in insulin
levels (Figures S1E–S1H).
Consistent with the plasma lipid values, we observed a 28%
increase of aortic root atherosclerotic lesion area (p < 0.05)
(Figures 1H and 1I). There was no difference in necrotic core
area (Figure S1I). The phenotype was present in both genders
and was independent of macrophage function, as it failed to
be transferred by transplanting bone marrow from
SirBACO:Ldlr/ into Ldlr/ mice (data not shown).
SirT1 Increases Hepatic Lipid Content and Secretion
in WTD-Fed Mice
To determine the role of SirT1 in the observed phenotype of
euglycemia with dyslipidemia, we first analyzed the effect of
WTD on hepatic SirT1 expression in wild-type C57BL/6 mice.
SirT1 levels rose 2-fold following 2 weeks on WTD, as did
Acc, Fas, and Pparg levels (Figure 2A). Thus, the transgenic
Sirt1 gain of function can be viewed as mimicking a pathophysi-
ological response to WTD. Conversely, Sirt1/ mice show
decreased levels of Fas and Acc1 in basal conditions (Fig-
ure S2A). Due to their poor health, a more detailed characteriza-
tion of these mice was not possible.
Next, we examined the regulation of glucose and lipid metab-
olism in SirBACO mice independently of the Ldlr deletion. On
a normal diet, these mice have normal metabolic parameters
(Figures S2B and S2C). Strikingly, 2 weeks of WTD recapitulated
aspects of the SirBACO:Ldlr/ mouse phenotype. Thus,
glucose levels were significantly lower and glucose tolerance
greater in WTD-fed SirBACO compared to control mice (Figures
2B and 2C) with normal insulin levels (Figure S2D), while TG rose
in both ad lib and fasted conditions (Figures 2D, S2E, and S2F).
We observed similar trends with longer duration of the diet (data
not shown).
To examine the mechanism of lipid abnormalities, we
measured hepatic lipid synthesis, content, and secretion.
Hepatic de novo lipogenesis demonstrated a trend toward
increased levels (Figure S2G); TG and cholesterol content
increased (Figures 2E–2G) in a SirT1 copy number-dependent
fashion in SirBACO hemizygous and homozygous mice. Secre-
tion of TG (Figure 2H), cholesterol (Figure 2I), and the main
VLDL apoprotein, ApoB48 (Figures 2J and 2K) (Ginsberg et al.,
2005), also rose.
Analyses of gene expression showed increased levels of
mRNAs encoding lipogenic enzymes and their transcriptional
regulators, including peroxisome proliferator-activated receptor
gamma (Pparg), Srebp-1c (Srebf1), fatty acid synthase (Fasn),
acetyl-CoA carboxylase 2 (Acacb), diacylglycerol O-acyltrans-
ferase 2 (Dgat2), and stearoyl-coenzyme A desaturase 1Cell Metabolism 14, 758–767, December 7, 2011 ª2011 Elsevier Inc. 759
Figure 2. Transgenic Overexpression of Sirt1 Increases Hepatic Lipid Content and Secretion upon WTD Feeding
(A) Western blot analysis of liver proteins from male C57BL/6J mice after 4 weeks WTD feeding. Mice were fasted for 7 hr. Dbc1 is used as a loading control.
(B–K) Metabolic analyses of SirBACOmice and control littermates (WT) after 2 weeks of WTD, including glucose (B) (n = 10–11 each), IPGTT (C) (n = 5–6 each),
plasma TG (D) (n = 10–11 each), hepatic H&E and oil red O staining (E), hepatic TG (F), and cholesterol content (G) following an 8 hr fast (n = 6–10).
(H and I) Triton assays to measure TG (H) and cholesterol secretion (I) (n = 6–7 each).
(J) Representative ApoB western blot following Triton injection.
(K) Quantification of multiple Triton secretion experiments (n = 5 each).
(L) Quantitative PCR analysis of hepatic gene expression (n = 5 each). In all experiments, **p < 0.01, *p < 0.05. Data are expressed as means ± SEM.
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(Srebf2) (Figure 2L) and its target genes Ldlr and Pcsk9 (Fig-
ure S2H) were unchanged. We also observed increases of fatty760 Cell Metabolism 14, 758–767, December 7, 2011 ª2011 Elsevieracid b-oxidative genes Ppara and peroxisomal acyl-CoA
oxidase (Acox) (Figure S2G). Thus, metabolic and gene expres-
sion data support the conclusion that SirT1 gain of functionInc.
Figure 3. SirT1 Modulates Creb Activity in
Liver
(A) Western blots of liver proteins from WTD-fed
mice (quantification in Figure S3A).
(B) Immunohistochemical staining of phospho-
Ser133 Creb in WTD-fed mice. Eight-week-old
mice were fasted for 8 hr prior to isolating livers for
analysis.
(C) Q-PCR analysis of hepatic gene expression in
mice on WTD for 2 weeks. Mice were fasted for
24 hr and then refed for 16 hr for RNA extraction
(*p < 0.05, n = 5 each). Data are expressed as
means ± SEM.
(D) Western blot analysis of liver proteins from
8-week-old Sirt1 heterozygous knockouts
(Sirt1+/) and control littermates (Sirt1+/+).
(E) Western blots of liver proteins from 12-week-
old ob/obmice and control littermates. Mice were
fasted overnight prior to analysis. Dbc1 is used as
a loading control.
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to WTD.
SirT1 Gain of Function Decreases Creb Acetylation
To understand the mechanism of decreased plasma glucose
and increased liver fat content and secretion, we examined
Akt activation, but failed to detect statistically significant differ-
ences in phospho-Akt or its substrate phosphor-Gsk3b
between SirBACO and control mice (Figures 3A and S3A).
These data are consistent with normal insulin signaling in
SirBACO:Ldlr/ mice (Figure S1J) and with our previous data
in SirBACOmice under different experimental conditions (Banks
et al., 2008).
Creb activates gluconeogenesis (Herzig et al., 2001) and
inhibits lipid synthesis (Herzig et al., 2003). Hence, decreased
Creb activity could explain the phenotype of WTD-fed SirBACO
mice. We hypothesized that SirT1 gain of function could inhibit
Creb function through deacetylation, resulting in decreased
gluconeogenesis and elevated lipogenesis. Indeed, Creb acety-Cell Metabolism 14, 758–767,lation was nearly absent in SirBACO
mice, and phosphorylation of Ser133—
the site required for Creb activation
(Chrivia et al., 1993)—was substantially
decreased when assessed by either
western blotting (Figure 3A) or immuno-
histochemistry. The latter change
occurred in a SirT1 transgene copy
number-dependent manner (Figure 3B).
Expression of most Creb target genes
was lower, consistent with decreased
Creb activity. Thus, levels of insulin
receptor substrate-2 (Irs2) and Nur77,
a gene that promotes gluconeogenesis
and inhibits lipogenesis (Chao et al.,
2007; Pols et al., 2008), decreased, as
did mRNA levels encoding Nur77
(encoded by Nr4a1), Irs2, Igfbp1, and
neuron-derived orphan receptor-1 Nor1(encodedbyNr4a3). Pparg, a target of Creb-dependent suppres-
sion (Herzig et al., 2003), showed increased levels, consistent
with decreased Creb activity (Figure 3A). The only Creb target
gene that was discordant with this pattern was Nurr1 (Nr4a2),
whose levels rose by 50% (Figure 3C). These data indicate
that Creb deacetylation is accompanied by decreased expres-
sion of most—but not all—of Creb target genes.
Both SirT1 and Creb are active in fasted conditions (Mayr and
Montminy, 2001; Schwer and Verdin, 2008). Accordingly, we did
not detect differences in Creb phosphorylation, acetylation,
Creb-dependent gene expression, and liver fat accumulation in
refed mice (Figures S3B–S3E).
SirT1 Loss of Function Activates Creb
Next, we assessed Creb acetylation and phosphorylation in
animals with reduced SirT1 levels. Sirt1 haploinsufficient mice
showed increased acetyl-Creb and phospho-Creb (Figure 3D).
In the liver of ob/ob mice, a genetic model of insulin resistance
and obesity, total Creb levels were decreased, but the ratio ofDecember 7, 2011 ª2011 Elsevier Inc. 761
Figure 4. SirT1 Regulates Creb Acetylation
and Phosphorylation
(A) Western blots of anti-FLAG immunoprecipi-
tates obtained from 293 cells overexpressing
FLAG-tagged Creb following treatment with 1 mM
trichostatin A (TSA) and 5 mM nicotinamide (Ntm)
for the indicated times.
(B) Western blots of extracts from 293 cells
transfected with FLAG-tagged Creb in combina-
tion with Cbp or SirT1.
(C) CRE-luciferase assays from McA-RH7777
cells transduced with GFP or SirT1 adeno-
virus. (*p < 0.05, n = 3). Data are expressed as
means ± SEM.
(D) Immunoprecipitation of FLAG-Creb from 293
cells cotransfected with Cbp or SirT1.
(E) Coimmunoprecipitation of endogenous Creb
by FLAG-tagged WT or H363Y SirT1 mutant in
293 cells following 30 min treatment with for-
skolin (5 mM).
(F) Coimmunoprecipitation of SirT1 by FLAG-tag-
ged Creb in 293 cells.
(G) In vitro Creb deacetylation assay with purified
Creb and SirT1.
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expression (Figure 3E). These data indicate that SirT1 regulation
of Creb is not limited to the SirBACO model, but is mirrored in
models of insulin-resistant diabetes.
SirT1 Regulates Creb Activity through Deacetylation
We asked whether acetylation affects Creb activity. Concurrent
inhibition of class I/II histone deacetylases (HDACs) by trichosta-
tin A (TSA) and class III HDACs by nicotinamide increased Creb
Ser133 phosphorylation and acetylation without affecting phos-
phorylation levels of the Creb kinase PKA (Figure 4A), suggesting
that acetylation modulates Creb phosphorylation independent
of PKA. Indeed, overexpression of the Creb acetylase Cbp (Lu
et al., 2003) was sufficient to promote Creb phosphorylation,
while SirT1 overexpression blocked it (Figure 4B). In the pres-
ence of the SirT1 inhibitors, nicotinamide or EX527 (Napper
et al., 2005), forskolin-induced Creb phosphorylation increased
in magnitude and duration (Figure S4A), further supporting the762 Cell Metabolism 14, 758–767, December 7, 2011 ª2011 Elsevier Inc.notion that deacetylation of Creb by
SirT1 negatively regulates its activity.
We tested whether pharmacological
SirT1 inhibition affected Creb activity.
Consistent with the in vivo gene expres-
sion data, inhibition of SirT1 deacetylase
activity resulted in higher levels of Creb
targets Nur77, Nor1, Irs2, Igfbp1, and
glucose-6-phosphatase (encoded by
G6pc) in hepatoma cells (Figure S4B).
Conversely, SirT1 overexpression
repressed forskolin-induced Creb-lucif-
erase activity by 50%, and EX527 treat-
ment pre-empted Creb inhibition by
SirT1 (Figure 4C). Overexpression of
SirT1 in hepatoma cells had similar
effects, increasing expression of Pparg,Dgat2, Acaca, and Acacb and repressing Nur77, Tnf-a, Il-1a,
and Il-6 (Pfluger et al., 2008); the only discordant change was
Nurr1 (Figure S4C). These data suggest that SirT1 affects Creb
function via deacetylation.
Creb Is a SirT1 Substrate
We sought to determine whether Creb is a SirT1 substrate. We
transfected 293 cells with FLAG-tagged Creb, SirT1, and Cbp
in various combinations. Creb acetylation was enhanced by
Cbp (Figure 4D, top panel, lane 3) and decreased by SirT1 (Fig-
ure 4D, top panel, lane 2). The phosphorylation-deficient Creb
mutant M1 (S133A) was similarly deacetylated by SirT1,
suggesting that deacetylation does not require Ser133 phos-
phorylation (Figure S4D). We then asked whether SirT1 physi-
cally interacts with Creb. We detected endogenous Creb by
immunoblotting following immunoprecipitation of FLAG-SirT1
transfected in 293 cells (Figure 4E, lanes 2 and 3), demonstrating
that SirT1 binds to endogenous Creb and that this interaction is
Figure 5. Creb Lys136 Is a SirT1 Substrate
(A) Mass spectra obtained from FLAG-Creb isolated from 293 cells co-
transfected with Cbp (+Cbp) or control DNA (Cbp).
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Cell Munaffected by Creb phosphorylation. Conversely, we detected
SirT1 by immunoblotting of Creb immunoprecipitates obtained
from cells coexpressing SirT1 and FLAG-tagged Creb (Fig-
ure 4F). Notably, unlike the SirT1-interacting protein Dbc1
(Zhao et al., 2008), Creb bound the mutant SirT1 H355Y, albeit
with reduced efficiency (Figure 4E, lane 4).
To demonstrate that SirT1 deacetylates Creb directly, and not
through interactions with Cbp or Torc2 (Liu et al., 2008), we per-
formed in vitro deacetylation assays with purified FLAG-Creb
and SirT1. Addition of SirT1 to the reaction mix resulted in
complete Creb deacetylation that was entirely reversed by the
SirT1 inhibitor, nicotinamide (Figure 4G). Next, we askedwhether
repression of Creb by SirT1 requires the latter’s deacetylase
activity. In 293 cells, a catalytically inactive SirT1 mutant
(H355Y) (Banks et al., 2008) failed to repress Creb acetylation
and phosphorylation, while repression by wild-type SirT1 was
blunted by EX527 (Figure S4E), indicating that Creb inhibition is
dependent on the deacetylase activity of SirT1. We also saw
inhibition of Creb by SirT1 in adipocytes (Figure S4F), suggesting
that it is a general event.
SirT1 Deacetylates Creb on Lys136
To identify SirT1 deacetylation sites, we immunoprecipitated
Creb from cells expressing Cbp or control DNA, purified the
immunoprecipitated protein from polyacrylamide gels, and sub-
jected it to MALDI-MS and LC-MS/MS. Out of 15 lysine residues
present in Creb, 10 are clustered in the bZIP domain, and 2
(Lys123 and Lys136) are adjacent to the cAMP-dependent phos-
phorylation site, Ser133 (Figure S5A). We detected acetyl-
Lys136, but not acetyl-Lys123 (Figure 5A). Interestingly,
Lys136 is the only lysine residue in this region conserved across
Creb homologs in different species (Figure S5A).
To evaluate the role of Lys136 inCreb function,wemutated it to
glutamine (K136Q) as acetylation mimetic or to arginine (K136R)
as deacetylation mimetic. Neither mutation affected Creb
binding to SirT1, but both decreased Cbp-dependent Creb
acetylation (Figure 5B), consistent with the notion that this is a
site of Creb acetylation in intact cells (Lu et al., 2003). Moreover,
both mutations pre-empted the ability of SirT1 inhibitors to stim-
ulate Creb phosphorylation (Figure S5B), indicating that Lys136
is the acetylation site involved in regulating Creb activation.
Time course analyses of forskolin induction indicated that
phosphorylation of the K136Q mutant was more rapid and long(B) Immunoprecipitation of FLAG-taggedWT, K136Q, or K136R Creb from 293
cells cotransfected with Cpb or SirT1.
(C) Western blots of protein extracts from 293 cells transfected with WT,
K136Q, or K136R Creb after 5 mM forskolin treatment for the indicated times.
(D) Western blot of 293 cells expressing wild-type Creb (WT), K136Q (KQ), or
K136R (KR) mutant. Cells were harvested after 30 min forskolin treatment at
indicated doses.
(E) CRE-luciferase assays from McA-RH7777 cells transfected with WT,
K136Q, or K136R Creb (**p < 0.01, *p < 0.05, n = 4).
(F–H) Effects of in vivo transduction of C57BL/6Jmicewith wild-type (Ad-Creb)
or K136Q (Ad-K136Q) Creb adenoviruses after 1 week on WTD. Mice were
fasted overnight and then refed for 4 hr.
(F) Plasma TG levels (*p < 0.05 versus GFP control, n = 6–7).
(G) Hepatic de novo lipogenesis (*p < 0.05 versus GFP control, n = 6–7).
(H) Q-PCR analysis of hepatic gene expression (**p < 0.01, *p < 0.05 versus
GFP control, n = 6). Data are expressed as means ± SEM.
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Figure 6. Creb K136Q Prevents Lipid Abnormalities in WTD-Fed
SirBACO Mice
(A–C) Hepatic lipid content characterized by oil red O staining (A), TG (B), and
cholesterol measurements (C) (n = 7–9 each).
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764 Cell Metabolism 14, 758–767, December 7, 2011 ª2011 Elsevierlasting, while that of the K136R mutant was more slow and short
lived than WT (Figure 5C). The K136Q mutant mimicked the
effect of SirT1 inhibition (Figure S5B). Dose-response studies
showed that the K136Q mutation increased Creb sensitivity to
forskolin-induced phosphorylation, whereas the K136R muta-
tion restored it to normal (Figure 5D). Moreover, in CRE transac-
tivation assays, the K136Qmutant increased Creb reporter gene
activity, while the K136R mutant decreased it compared to WT
Creb, indicating that the acetylation state of K136 directly affects
Creb activity (Figure 5E). To sum up, these data show that
Lys136 acetylation increases Creb sensitivity to PKA-dependent
phosphorylation.
Gene expression studies in hepatoma cells further support
these conclusions. Expression of K136Q resulted in greater
basal or forskolin-induced levels of phosphoenolpyruvate-car-
boxykinase (Pck1), Igfbp1, G6pc, Nur77, Nor1, and Nurr1 and
suppressed Fasn and Acaca (Figure S5C), mirroring the effects
seen in SirBACO mice and supporting the idea that acetylation
activates Creb. In addition, the ability of insulin to suppress for-
skolin-induced expression of Pck1, Igfbp1, and G6pc was
impaired. The lipogenic genes do not respond to insulin induc-
tion in this cell type, so this aspect of the phenotype could not
be properly evaluated.
K136Q Mutant Creb Reverses the Phenotype
of WTD-Fed SirBACO Mice
To study the metabolic consequences of the K136Q mutation
in vivo, we transduced C57BL mice with adenoviruses encoding
WT or K136Q mutant Creb and subjected them to WTD. The
adenoviruses affected neither glucose levels nor glucose toler-
ance (Figures S5D–S5G), but the K136Q mutant did decrease
plasma TG and lowered hepatic de novo lipogenesis, as as-
sessed by tracer methods, by nearly 50% (Figures 5F and 5G).
In addition, expression of lipogenic genes (Srebf1, Fasn) was
decreased while that of glucogenic genes (Pgc1a, Pck1,
Nur77) was increased, consistent with the notion that Creb acet-
ylation mimics Creb activation by cAMP (Figure 5H).
Next, we evaluated the ability of the K136Q mutant Creb to
prevent WTD-induced dyslipidemia and steatosis in SirBACO
mice. We administered adenoviruses encoding WT or K136Q
mutant Creb toSirBACOmice and control littermates and placed
them on WTD. After 2 weeks on the diet, SirBACO mice treated
with WT Creb still demonstrated the same abnormalities seen in
untreated mice: increased hepatic lipid, as well as plasma TG
and cholesterol, lower blood glucose, and unchanged insulin
levels compared to control littermates (Figures 6A–6G). In
contrast, SirBACO mice treated with Ad-K136Q showed
glucose, TG, and cholesterol levels similar to wild-type controls
in the fasted or refed states (Figures 6E–6G, S6A, and S6B).
Administration of Ad-K136Q also prevented diet-induced weight(D) Liver weight (n = 7–9).
(E–G) Plasma TG (D), glucose (E), and insulin (F) after 24 hr fasting (Fasted)
followed by 4 hr refeeding (Refed) (n = 7–9).
(H–J) Changes in body weight (H) and composition with lean (I) and fat mass
(J) n = 7–9) during WTD feeding. In all experiments **p < 0.01 and *p < 0.05.
Open bar, Ad-Creb inWTmice; black bar, Ad-Creb in SirBACOmice; blue bar,
Ad-K136Q in WT mice; red bar, Ad-K136Q in SirBACO mice. Data are ex-
pressed as means ± SEM.
Inc.
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mice (Figures 6H–6J and S6C). These data show that preventing
Creb deacetylation reverses the metabolic features of WTD-fed
SirBACO mice.
DISCUSSION
The question addressed in this work waswhether SirT1, by virtue
of its ability to prevent diabetes (Banks et al., 2008; Pfluger et al.,
2008), would also protect against atherosclerosis. Surprisingly,
our investigations reveal an apparent proatherogenic phenotype
in mice carrying an extra copy of Sirt1.
Are Sirtuins Good or Bad for Atherosclerosis?
The link between SirT1 and lipid metabolism has been the
subject of intense investigation. Sirt1/ mice display reduced
HDL cholesterol and TG and a blunted response to LXR agonists
that has been linked to reduced SirT1-dependent activation of
LXR through deacetylation (Li et al., 2007). The predisposition
of SirBACO mice to WTD-induced hepatosteatosis and the rise
of plasma TG are consistent with these findings; however, we
found no evidence of increased HDL cholesterol, as would be
expected based on the Sirt1/ phenotype, nor did we see
changes in cholesterol efflux and foam cell formation from
SirBACOmacrophages (data not shown). Potential explanations
for this discrepancy include variations in genetic background
and SirT1 expression levels or source of macrophages (Li
et al., 2007).
The phenotype of liver-specific SirT1 ablation is also consis-
tent with that of SirBACOmice: decreased liver fat accumulation
in response to WTD, lower Srebf1 and Fasn levels (Chen et al.,
2008), as well as decreased Pparg-dependent gene expression,
increased inflammation, and ER stress (Purushotham et al.,
2009). In our study we observed decreased inflammation and
ER stress (Figure S3F), as was seen in another model of SirT1
gain of function (Pfluger et al., 2008). Unlike the latter study,
we saw increased hepatosteatosis in WTD-fed SirBACO mice.
Although it is possible that this apparent discrepancy is due to
the different diets used in the two studies (cholesterol-rich versus
high-fat), we should point out that in our previous work we didn’t
see protection from hepatosteatosis in high-fat-fed SirBACO
mice that were protected from diabetes, as documented by
glucose clamps and other metabolic data (Banks et al., 2008).
The explanation for the difference between the two transgenic
lines may not be unrelated to unusual features of the mice
studied by Pfluger et al.: (1) extreme insulin sensitivity on the
normal diet (low body weight, near-undetectable fasting insulin
levels, near-flat glucose excursions during GTT) and (2) unchar-
acteristic response to the diet, in which glucose levels remained
unchanged compared to the normal diet, insulin levels remained
low, and yet glucose and insulin tolerance became altered in
wild-type mice (Pfluger et al., 2008).
Previous work demonstrated antiatherogenic effects of SirT1
in macrophages and vascular endothelial cells (Zhang et al.,
2008). The design of our study allowed us to parse the integrated
contribution of SirT1 gain of function in different tissues to
atherosclerosis. Our data indicate that the proatherogenic
effects of SirT1 on hepatic lipid metabolism trump its ‘‘periph-
eral’’ benefits on macrophages and vasculature. In fact,Cell MSirBACO macrophages appear to have largely normal functions
in cholesterol uptake and inflammation and failed to affect
atherosclerosis development in bone marrow transfer experi-
ments (data not shown).
We conclude that the effects of SirT1 are pleiotropic and that in
type 2 diabetes, sirtuin agonists might have undesired effects on
lipid metabolism. However, such effects seemingly arise from
increased insulin sensitivity, not from insulin resistance, adding
to a growing body of evidence that suggests that excessive
insulin action, as opposed to insulin resistance, predisposes to
the characteristic plasma lipid profile of type 2 diabetes (Han
et al., 2009).
Sirtuins and Polyphenols
Polyphenols like resveratrol have been suggested to promote
sirtuin activity (Howitz et al., 2003), but their effect on hepatic
lipid metabolism stands in apparent contrast to the phenotype
of SirBACO mice (Baur et al., 2006; Hou et al., 2008). In light of
the demonstration that polyphenols activate AMPK (Canto´
et al., 2009; Lagouge et al., 2006), we suggest that their meta-
bolic effects are independent of SirT1. Alternatively, it is possible
that their effect exceeds that of a single extra copy of Sirt1 in
SirBACO mice; however, in view of the fact that key SirT1
substrates are hypoacetylated in SirBACO mice (Banks et al.,
2008; Pfluger et al., 2008), this explanation seems unlikely.
Two Fasting Signals
The identification of Creb as a bona fide SirT1 substrate reveals
a biochemical and genetic pathway linking two critical ‘‘fasting’’
signals: cAMP and NAD+. It also allows us to integrate these two
proteins with another regulator of the fasting response, FoxO1
(Accili andArden, 2004). Interestingly, acetylation plays a permis-
sive role in FoxO1 (Qiang et al., 2010) and Creb phosphorylation
(this report). But phosphorylation inactivates FoxO1 while acti-
vating Creb. It can thus be envisioned that SirT1 activation in
response to falling nutrient levels promotes a shift from Creb-
to FoxO1-dependent metabolism (Liu et al., 2008), leading to
increased lipid utilization. Our findings can also help reconcile
conflicting reports on Creb and lipid metabolism. While domi-
nant-negative Creb (A-Creb) or Creb RNAi cause liver steatosis
in mice (Herzig et al., 2003), Creb inhibition by antisense oligonu-
cleotide results in lower plasma and liver cholesterol and TG in
diabetic rats but not in ob/obmice (Erion et al., 2009). The disso-
ciation between Creb levels and its phosphorylation/acetylation
in ob/obmice indicates that changes in acetylation can offset the
effects of decreased protein levels.
Two recent findings in human studies support our conclusions
that Creb regulates lipid metabolism: clinical trials of glucagon
receptor antagonists demonstrate an improvement of glucose
levels in patients with diabetes associated with a rise in LDL
cholesterol (S.S. Engel et al., 2011, American Diabetes Associa-
tion, meeting abstract). Also, genetic mutations of the Creb
family gene CrebH are associated with alterations of TG clear-
ance leading to hypertriglyceridemia (Lee et al., 2011). Thus,
we tentatively propose that the mechanism identified in our
study is relevant to human disease pathophysiology.
In summary, we demonstrate a dyslipidemic effect of SirT1
gain of function, mediated through Creb deacetylation. This
effect might limit the therapeutic value of SirT1 agonists inetabolism 14, 758–767, December 7, 2011 ª2011 Elsevier Inc. 765
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SirT1, Creb, and Atherosclerosisdiabetes treatment. Further studies of the pathway linking SirT1
and Creb will provide alternative approaches to the modulation
of lipid metabolism by insulin sensitizers.
EXPERIMENTAL PROCEDURES
Reagents
We cultured McA-RH7777 and HEK293T cells (ATCC, Manassas, VA) in
DMEM with 10% fetal bovine serum (Mediatech, Inc., Manassas, VA). We
used Hygromycin B (Sigma-Aldrich) to select for stable clones expressing
CRE-luciferase. We used the following antibodies: monoclonal and poly-
clonal anti-acetylated-lysine, p-Akt (T308 or S473), p-Creb, total Creb,
p-AMPK (Cell Signaling); Fas, PPARg, cyclophilin A, p-PKA, a-tubulin,
RXRa, FXR (Santa Cruz); SirT1, Irs2, p-Acc (Millipore-Upstate); mouse
Nur77 (eBioscience); Dbc1 (Bethyl Laboratories); FLAG M2 (Sigma-Aldrich);
LXRa (R&D Systems); and apoB and HA (Abcam). Expression vectors for
FLAG-Creb (#22968) and phosphorylation-defective Creb-M1 (#22969)
were from Addgene (Cambridge, MA). Creb-K136Q and Creb-K136R
mutants were made by site-directed mutagenesis (GenScript USA Inc.,
Piscataway, NJ). Creb-K136Q adenoviruses were made and purified by
Welgen, Inc. (Worcester, MA). FLAG-SirT1 and SirT1-H363Y were cloned
into pEGFP-N1 for transient expression. pGL4.29[luc2P/CRE/Hygro] was
from Promega (Madison, WI), and TransIT-LT1 transfection reagent was
from Mirus Bio LLC (Madison, WI).
Mice
SirBACOmice on C57BL/6J background (Banks et al., 2008) were mated with
Ldlr/ mice to generate SirBACO:Ldlr/ mice. Sirt1+/ mice have been
described (Li et al., 2007), and C57BL/6J and Lepob/+mice were from Jackson
Laboratory (Bar Harbor, ME). The western diet used in these experiments
contains 42% milk fat and 0.15% cholesterol (TD88137, Harlan Teklad).
Atherosclerotic lesions were analyzed as described (Han et al., 2006). All
adenovirus administrations were at a dose of 1 3 109 vp/g. The Columbia
University Animal Care and Utilization Committee have approved all animal
experiments.
Protein Studies
For native immunoprecipitation, we lysed cells in FLAG IP buffer (50 mM Tris
[pH 7.4], 150 mM NaCl, 0.2% Triton X-100, 10% glycerol) supplemented
with 2 mM TSA (Sigma-Aldrich), 10 mM nicotinamide (Sigma-Aldrich), and
protease and phosphatase inhibitors (Boston Bioproducts) and incubated
1 mg protein with anti-FLAG M2 affinity gel (Sigma-Aldrich) overnight at 4C.
After four washes with FLAG IP buffer, proteins were eluted by 33 FLAG
peptides in FLAG IP buffer. Acetylated-lysine IP was carried out following
W.P. Tansey’s protocol. Mouse tissue was lysed in TSD buffer (50 mM Tris
[pH 7.4], 1% sodium dodecyl sulfate [SDS], 5 mM DTT) with 2 mM TSA and
10 mM nicotinamide, boiled for 10 min, and centrifuged. Thereafter, we trans-
ferred 0.6 mg protein to 1.2 ml TNN buffer (50 mM Tris [pH 7.4], 250 mM NaCl,
5 mM EDTA, and 0.5% NP-40) with inhibitors, preabsorbed with 50 ml protein
A/G agarose slurry (Santa Cruz), and immunoprecipitated using 5 ml anti-acet-
ylated-lysine antibody (Cell Signaling). Immune complexes were bound to
protein A/G agarose slurry, extensively washed, and eluted by boiling in
0.1 ml sample buffer.
For western blotting, we lysed cells or tissues in buffer containing 20mMTris
(pH 7.4), 150 mM NaCl, 10% glycerol, 2% NP-40, 1 mM EDTA (pH 8.0), 0.2%
SDS, and 0.5% NaDOC supplemented with protease and phosphatase inhib-
itors. Proteins were denatured under reducing condition and separated on
SDS-PAGE prior to western blotting using either ECL substrate kit (Thermo
Scientific) or Odyssey Infrared Imagining System (LI-COR Biosciences).
Gene Expression Analysis
We isolated RNA with RNeasy kit (QIAGEN) and DNase I (QIAGEN) digestion,
synthesized cDNAwith high-capacity cDNA Reverse Transcription kit (Applied
Biosystems), and performed quantitative real-time PCR (qPCR) with goTaq
qPCR Master Mix (Promega) on Bio-Rad CFX96 Real-Time PCR system.
Expression levels were calculated by DDCt method using murine cyclophilin
A or rat 36B4 as controls. Primer sequences are in Table S1.766 Cell Metabolism 14, 758–767, December 7, 2011 ª2011 ElsevierMetabolic Measurements
TG secretion was measured following intravenous injection of Triton WR-1339
(0.5 mg/g body weight) (Sigma-Aldrich) in 5 hr fasted mice (Han et al., 2009).
Blood samples were collected in EDTA capillaries. Hepatic lipids were
extracted as described (Folch et al., 1957). Metabolites were measured with
NEFA-HR(2), Cholesterol E, HDL-Cholesterol E (Wako Diagnostics), Infinity
Triglyceride Reagent (Thermo Scientific), Mouse Insulin ELISA (Millipore),
and OneTouch Glucometer (Lifescan, Inc.).
De Novo Lipogenesis Assay
Hepatic de novo lipogenesis was measured as described (Zhang et al., 2006),
using 1 mCi 3H2O (American Radiolabeled Chemicals) per mouse.
Histological Analysis
We used paraffin-embedded liver sections for hematoxylin and eosin and
frozen sections for oil red O staining. Immunohistochemical analysis of phos-
pho-Creb in paraffin-embedded liver sections was carried out using phospho-
Creb (Ser133) (87G3) antibody (Cell Signaling) at a dilution of 1:50 with
dehydration.
Luciferase Assay
McA-RH7777 cells stably overexpressing CRE-driven luc2P were infected
with SirT1 adenovirus at moi = 1 and pretreated with 10 mM EX527 overnight
prior to 100 mM forskolin for 5 hr. Luciferase activity was determined with
Bright-Glo Luciferase Assay System (Promega).
Statistical Analysis
We used unpaired two-tailed Student’s t test to evaluate differences and the
customary value p < 0.05 to declare statistical significance. All values are ex-
pressed as means ± standard error of means (SEM).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures and one table and can be found
with this article online at doi:10.1016/j.cmet.2011.10.007.
ACKNOWLEDGMENTS
We thank R. Haeusler, K. Tsuchiya, A. Tall, I. Tabas, and G. Li for critical
discussion of the data; W. Zhao, N. Kon, Y. Tang, and M. Li for help with acet-
ylation studies; J. Reusch and S. Pugazhenthi for Creb adenovirus; T. Kolar
and A. Flete for technical support; and G. Heinrich for critical reading of the
manuscript. This work was supported by NIH grants HL087123 and
DK063608 (Columbia Diabetes and Endocrinology Research Center).
Received: March 10, 2011
Revised: September 2, 2011
Accepted: October 4, 2011
Published online: November 10, 2011
REFERENCES
Accili, D., and Arden, K.C. (2004). FoxOs at the crossroads of cellular metab-
olism, differentiation, and transformation. Cell 117, 421–426.
Banks, A.S., Kon, N., Knight, C., Matsumoto, M., Gutie´rrez-Jua´rez, R.,
Rossetti, L., Gu, W., and Accili, D. (2008). SirT1 gain of function increases
energy efficiency and prevents diabetes in mice. Cell Metab. 8, 333–341.
Baur, J.A., Pearson, K.J., Price, N.L., Jamieson, H.A., Lerin, C., Kalra, A.,
Prabhu, V.V., Allard, J.S., Lopez-Lluch, G., Lewis, K., et al. (2006).
Resveratrol improves health and survival of mice on a high-calorie diet.
Nature 444, 337–342.
Biddinger, S.B., Hernandez-Ono, A., Rask-Madsen, C., Haas, J.T., Alema´n,
J.O., Suzuki, R., Scapa, E.F., Agarwal, C., Carey, M.C., Stephanopoulos, G.,
et al. (2008). Hepatic insulin resistance is sufficient to produce dyslipidemia
and susceptibility to atherosclerosis. Cell Metab. 7, 125–134.
Canto´, C., Gerhart-Hines, Z., Feige, J.N., Lagouge, M., Noriega, L., Milne, J.C.,
Elliott, P.J., Puigserver, P., and Auwerx, J. (2009). AMPK regulates energyInc.
Cell Metabolism
SirT1, Creb, and Atherosclerosisexpenditure by modulating NAD+ metabolism and SIRT1 activity. Nature 458,
1056–1060.
Chao, L.C., Zhang, Z., Pei, L., Saito, T., Tontonoz, P., and Pilch, P.F. (2007).
Nur77 coordinately regulates expression of genes linked to glucose metabo-
lism in skeletal muscle. Mol. Endocrinol. 21, 2152–2163.
Chen, D., Bruno, J., Easlon, E., Lin, S.J., Cheng, H.L., Alt, F.W., and Guarente,
L. (2008). Tissue-specific regulation of SIRT1 by calorie restriction. Genes Dev.
22, 1753–1757.
Chrivia, J.C., Kwok, R.P., Lamb, N., Hagiwara, M., Montminy, M.R., and
Goodman, R.H. (1993). Phosphorylated CREB binds specifically to the nuclear
protein CBP. Nature 365, 855–859.
Erion, D.M., Yonemitsu, S., Nie, Y., Nagai, Y., Gillum, M.P., Hsiao, J.J.,
Iwasaki, T., Stark, R., Weismann, D., Yu, X.X., et al. (2009). SirT1 knockdown
in liver decreases basal hepatic glucose production and increases hepatic
insulin responsiveness in diabetic rats. Proc. Natl. Acad. Sci. USA 106,
11288–11293.
Folch, J., Lees, M., and Sloane Stanley, G.H. (1957). A simple method for the
isolation and purification of total lipides from animal tissues. J. Biol. Chem.
226, 497–509.
Ginsberg, H.N., Zhang, Y.L., and Hernandez-Ono, A. (2005). Regulation of
plasma triglycerides in insulin resistance and diabetes. Arch. Med. Res. 36,
232–240.
Haeusler, R.A., and Accili, D. (2008). The double life of Irs. Cell Metab. 8, 7–9.
Han, S., Liang, C.P., DeVries-Seimon, T., Ranalletta, M., Welch, C.L., Collins-
Fletcher, K., Accili, D., Tabas, I., and Tall, A.R. (2006). Macrophage insulin
receptor deficiency increases ER stress-induced apoptosis and necrotic
core formation in advanced atherosclerotic lesions. Cell Metab. 3, 257–266.
Han, S., Liang, C.P., Westerterp, M., Senokuchi, T., Welch, C.L., Wang, Q.,
Matsumoto, M., Accili, D., and Tall, A.R. (2009). Hepatic insulin signaling regu-
lates VLDL secretion and atherogenesis in mice. J. Clin. Invest. 119, 1029–
1041.
Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D.,
Schutz, G., Yoon, C., Puigserver, P., et al. (2001). CREB regulates hepatic
gluconeogenesis through the coactivator PGC-1. Nature 413, 179–183.
Herzig, S., Hedrick, S., Morantte, I., Koo, S.H., Galimi, F., and Montminy, M.
(2003). CREB controls hepatic lipid metabolism through nuclear hormone
receptor PPAR-gamma. Nature 426, 190–193.
Hou, X., Xu, S., Maitland-Toolan, K.A., Sato, K., Jiang, B., Ido, Y., Lan, F.,
Walsh, K., Wierzbicki, M., Verbeuren, T.J., et al. (2008). SIRT1 regulates hepa-
tocyte lipid metabolism through activating AMP-activated protein kinase.
J. Biol. Chem. 283, 20015–20026.
Howard, G., O’Leary, D.H., Zaccaro, D., Haffner, S., Rewers, M., Hamman, R.,
Selby, J.V., Saad, M.F., Savage, P., and Bergman, R.; The Insulin Resistance
Atherosclerosis Study (IRAS) Investigators. (1996). Insulin sensitivity and
atherosclerosis. Circulation 93, 1809–1817.
Howitz, K.T., Bitterman, K.J., Cohen, H.Y., Lamming, D.W., Lavu, S., Wood,
J.G., Zipkin, R.E., Chung, P., Kisielewski, A., Zhang, L.L., et al. (2003). Small
molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.
Nature 425, 191–196.
Lagouge, M., Argmann, C., Gerhart-Hines, Z., Meziane, H., Lerin, C., Daussin,
F., Messadeq, N., Milne, J., Lambert, P., Elliott, P., et al. (2006). ResveratrolCell Mimproves mitochondrial function and protects against metabolic disease by
activating SIRT1 and PGC-1alpha. Cell 127, 1109–1122.
Lee, J.H., Giannikopoulos, P., Duncan, S.A., Wang, J., Johansen, C.T., Brown,
J.D., Plutzky, J., Hegele, R.A., Glimcher, L.H., and Lee, A.H. (2011). The tran-
scription factor cyclic AMP-responsive element-binding protein H regulates
triglyceride metabolism. Nat. Med. 17, 812–815.
Li, X., Zhang, S., Blander, G., Tse, J.G., Krieger, M., and Guarente, L. (2007).
SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol.
Cell 28, 91–106.
Liu, Y., Dentin, R., Chen, D., Hedrick, S., Ravnskjaer, K., Schenk, S., Milne, J.,
Meyers, D.J., Cole, P., Yates, J., 3rd., et al. (2008). A fasting inducible switch
modulates gluconeogenesis via activator/coactivator exchange. Nature 456,
269–273.
Lu, Q., Hutchins, A.E., Doyle, C.M., Lundblad, J.R., and Kwok, R.P. (2003).
Acetylation of cAMP-responsive element-binding protein (CREB) by CREB-
binding protein enhances CREB-dependent transcription. J. Biol. Chem.
278, 15727–15734.
Mayr, B., and Montminy, M. (2001). Transcriptional regulation by the phos-
phorylation-dependent factor CREB. Nat. Rev. Mol. Cell Biol. 2, 599–609.
Napper, A.D., Hixon, J., McDonagh, T., Keavey, K., Pons, J.F., Barker, J., Yau,
W.T., Amouzegh, P., Flegg, A., Hamelin, E., et al. (2005). Discovery of indoles
as potent and selective inhibitors of the deacetylase SIRT1. J. Med. Chem. 48,
8045–8054.
National Institute of Diabetes and Digestive and Kidney Diseases. (2005).
National Diabetes Statistics fact sheet: general information and national esti-
mates on diabetes in the United States (Bethesda, MD: U.S. Department of
Health and Human Services, National Institute of Health).
Pfluger, P.T., Herranz, D., Velasco-Miguel, S., Serrano, M., and Tscho¨p, M.H.
(2008). Sirt1 protects against high-fat diet-induced metabolic damage. Proc.
Natl. Acad. Sci. USA 105, 9793–9798.
Pols, T.W., Ottenhoff, R., Vos, M., Levels, J.H., Quax, P.H., Meijers, J.C.,
Pannekoek, H., Groen, A.K., and de Vries, C.J. (2008). Nur77 modulates
hepatic lipid metabolism through suppression of SREBP1c activity.
Biochem. Biophys. Res. Commun. 366, 910–916.
Purushotham, A., Schug, T.T., Xu, Q., Surapureddi, S., Guo, X., and Li, X.
(2009). Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism
and results in hepatic steatosis and inflammation. Cell Metab. 9, 327–338.
Qiang, L., Banks, A.S., and Accili, D. (2010). Uncoupling of acetylation from
phosphorylation regulates FoxO1 function independent of its subcellular local-
ization. J. Biol. Chem. 285, 27396–27401.
Schwer, B., and Verdin, E. (2008). Conservedmetabolic regulatory functions of
sirtuins. Cell Metab. 7, 104–112.
Zhang, F., Hamanaka, R.B., Bobrovnikova-Marjon, E., Gordan, J.D., Dai, M.S.,
Lu, H., Simon, M.C., and Diehl, J.A. (2006). Ribosomal stress couples the
unfolded protein response to p53-dependent cell cycle arrest. J. Biol. Chem.
281, 30036–30045.
Zhang, Q.J., Wang, Z., Chen, H.Z., Zhou, S., Zheng, W., Liu, G., Wei, Y.S., Cai,
H., Liu, D.P., and Liang, C.C. (2008). Endothelium-specific overexpression of
class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-
deficient mice. Cardiovasc. Res. 80, 191–199.
Zhao,W., Kruse, J.P., Tang, Y., Jung, S.Y., Qin, J., andGu,W. (2008). Negative
regulation of the deacetylase SIRT1 by DBC1. Nature 451, 587–590.etabolism 14, 758–767, December 7, 2011 ª2011 Elsevier Inc. 767
